300204 Stock Overview
Staidson (Beijing) BioPharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.19 |
| 52 Week High | CN¥12.39 |
| 52 Week Low | CN¥5.41 |
| Beta | 0.50 |
| 11 Month Change | 0.86% |
| 3 Month Change | 28.37% |
| 1 Year Change | -27.65% |
| 33 Year Change | -62.94% |
| 5 Year Change | -20.79% |
| Change since IPO | -56.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300204 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 7.3% | -2.6% | -2.1% |
| 1Y | -27.7% | -20.9% | 2.8% |
Return vs Industry: 300204 underperformed the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 300204 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 300204 volatility | |
|---|---|
| 300204 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300204 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300204's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 547 | Wang Chao | www.staidson.com |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases.
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Fundamentals Summary
| 300204 fundamental statistics | |
|---|---|
| Market cap | CN¥3.91b |
| Earnings (TTM) | -CN¥223.29m |
| Revenue (TTM) | CN¥350.71m |
11.2x
P/S Ratio-17.5x
P/E RatioIs 300204 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300204 income statement (TTM) | |
|---|---|
| Revenue | CN¥350.71m |
| Cost of Revenue | CN¥71.97m |
| Gross Profit | CN¥278.74m |
| Other Expenses | CN¥502.02m |
| Earnings | -CN¥223.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 79.48% |
| Net Profit Margin | -63.67% |
| Debt/Equity Ratio | 0% |
How did 300204 perform over the long term?
See historical performance and comparison